The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB)...
The FDA recently approved AIMT's Palforzia as first ever treatment for peanut allergies, but for now, DBVT's Viaskin might only be months behind. It is difficul
Aimmune Therapeutics Inc (NASDAQ:AIMT) saw a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 16,550,000 shares, a growth of 7.0% from t
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vertex Pharmaceuticals (VRTX) and Apellis Pharmaceuticals (APLS). Vertex
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vertex Pharmaceuticals ( VRTX – Research Report ) and Apellis Pharmaceuticals ( APLS – Research Report ). Vertex P
Humana posts coverage determination for Aimmune's Palforzia AIMT HUM
Aimmune Therapeutics to Host Conference Call and Webcast to Discuss First Quarter 2020 Financial Results and Recent Operational Highlights
Zacks Investment Research upgraded shares of Aimmune Therapeutics (NASDAQ:AIMT) from a hold rating to a buy rating in a research note issued to investors on Monday, Zacks.com reports. The firm current
If you want to know who really controls Aimmune Therapeutics, Inc. (NASDAQ:AIMT), then you'll have to look at the...
The "Global Allergy Immunotherapies Market 2020-2024" report has been added to ResearchAndMarkets.com's offering.
Fly Insider: Accelerate Diagnostics, Abbott among week's notable insider trades MYOV AIMT AXDX CFG VOXX KMB PGNY EBS ABT ACAD
Aimmune Therapeutics Inc (NASDAQ:AIMT) major shareholder Des Produits Nestle S. Societe acquired 1,525,634 shares of Aimmune Therapeutics stock in a transaction that occurred on Friday, February 7th.
Aimmune Therapeutics Inc (NASDAQ:AIMT) major shareholder Health Science Us Holdi Nestle acquired 937,500 shares of the business’s stock in a transaction dated Wednesday, February 26th. The shares we
In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Aimmune Therapeutics (AIMT), with a price target of $66.00. The
In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Aimmune Therapeutics (AIMT – Research Report),
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE